Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.

ABSTRACT: Monoclonal antibodies (mAbs), the new revolutionary class of medications, are fast becoming tools against various diseases thanks to a unique structure and function that allow them to bind highly specific targets or receptors. These specialized proteins can be produced in large quantities via the hybridoma technique introduced in 1975 or by means of modern technologies. Additional methods have been developed to generate mAbs with new biological properties such as humanized, chimeric, or murine. The inclusion of mAbs in therapeutic regimens is a major medical advance and will hopefully lead to significant improvements in infectious disease management. Since the first therapeutic mAb, muromonab-CD3, was approved by the U.S. Food and Drug Administration (FDA) in 1986, the list of approved mAb

SUBMITTER: Mokhtary P 

PROVIDER: S-EPMC9405509 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature